Detalles de la búsqueda
1.
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.
Oncologist
; 29(6): e741-e749, 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38340010
2.
Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Oncologist
; 25(3): e469-e476, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162797
3.
Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy.
Support Care Cancer
; 28(12): 5943-5952, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32281034
4.
Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study.
J Cancer
; 14(14): 2644-2654, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37779870
5.
Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy.
J Pharm Health Care Sci
; 8(1): 8, 2022 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35236407
6.
Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
Lung Cancer
; 134: 1-6, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31319966
7.
Efficacy of Single-dose First-generation 5-HT3 Receptor Antagonist and Dexamethasone for Preventing Nausea and Vomiting Induced by Low-dose Carboplatin-based Chemotherapy.
Anticancer Res
; 37(4): 1965-1970, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28373467
Resultados
1 -
7
de 7
1
Próxima >
>>